Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Grade 2 IDH1-mutant Glioma · Grade 3 IDH1-mutant Glioma · Glioma · IDH1-mutant Glioma · Oligodendroglioma · Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted · Astrocytoma IDH Mutant Grade 3 · Astrocytoma IDH Mutant Grade 2
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Mar 2027
- Main results expected
- Sep 2030
- Fully finished
- Mar 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
Measured over: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07703436 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC